Premium
Use of pharmacoeconomics in prescribing research. Part 1: costs – moving beyond the acquisition price for drugs
Author(s) -
Robertson J.,
Lang D.,
Hill S.
Publication year - 2003
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.2003.00452.x
Subject(s) - formulary , pharmacoeconomics , purchasing , variety (cybernetics) , business , subsidy , economic evaluation , reimbursement , health economics , actuarial science , medicine , health care , economics , marketing , family medicine , economic growth , computer science , intensive care medicine , market economy , pathology , artificial intelligence
Summary This paper addresses pharmacoeconomics in prescribing research and reflects the increasing use of techniques of economic evaluation to aid drug purchasing decisions in a variety of settings – for national drug subsidization programmes, provincial purchasing plans, insurance programmes, and for hospital and area health authority formulary decisions. First, we focus on the cost component of an economic evaluation and discuss methodological issues that are relevant to all pharmacoeconomic analyses.